Sartorius AGSARTF 84 Debt-to-Equity is 1.58 as of Mar. 2026, which is 1% above its 10-year median of 1.57. GuruFocus rates SARTF with a GF Score™ of 84/100 and a GF Value™ of $220.63 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 704 Medical Devices & Instruments companies, Sartorius AG ranks worse than 92.05% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sartorius AG's Debt-to-Equity or its related term are showing as below:
SARTF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.95 Med: 1.57 Max: 2.6
Current: 1.58
During the past 13 years, the highest Debt-to-Equity Ratio of Sartorius AG was 2.60. The lowest was 0.95. And the median was 1.57.
SARTF's Debt-to-Equity is ranked worse than 92.05% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs SARTF: 1.58
Sartorius AG (OTCPK:SARTF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sartorius AG Debt-to-Equity Related Terms
Sartorius AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sartorius AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SARTF vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sartorius AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a Debt-to-Equity of 1.58 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sartorius AG and its competitors. This is near median its historical median of 1.57. Over the past decade, Sartorius AG's Debt-to-Equity has ranged from 0.95 to 2.60. According to the industry distribution chart, Sartorius AG ranks #648 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 92%.
Is Sartorius AG's Debt-to-Equity too high?
Sartorius AG's current Debt-to-Equity of 1.58 is near median its 10-year median of 1.57. Over the past 10 years, this metric has ranged from a low of 0.95 to a high of 2.60. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Sartorius AG's value of 1.58 is 602.2% above this industry median. Based on the distribution chart, Sartorius AG ranks #648 out of 704 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #648 out of 704 companies for Debt-to-Equity. This places Sartorius AG in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Sartorius AG's value of 1.58 is 602.2% above this benchmark. Historically, Sartorius AG's own Debt-to-Equity has ranged from 0.95 to 2.60 over the past decade. While the company's 10-year median is 1.57 vs. the industry median of 0.23, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current Debt-to-Equity of 1.58 is 602.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current Debt-to-Equity is 1.58, which is near median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $220.63, compared to a current price of $212.80 — trading 3.5% below its estimated fair value. The current Debt-to-Equity is 1.58, which is near median its 10-year median of 1.57 and 602.2% above the Medical Devices & Instruments industry median of 0.23. Sartorius AG's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Debt-to-Equity is 1.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 3.5% below its estimated GF Value™ of $220.63.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
Debt-to-Equity: 1.58 (near median its 10-year median of 1.57)
GF Value™: $220.63 vs. price of $212.80 (3.5% below fair value)
Industry Position: 602.2% above the Medical Devices & Instruments median (#648 of 704)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
84GF Score
Get the complete analysis for SARTF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
